Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.72 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30841475 | 1.00 | EPHX2 (0.72) | EPHX2EPHX1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19012103 | 0.84 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL22470475 | 0.82 | NPC1 (0.74) | EPHX2EPHX1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17130367 | 0.82 | EPHX2 (0.67) | EPHX2EPHX1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2718899 | 0.82 | EPHX1 (1.00) | EPHX2EPHX1 | |
| SCHEMBL31315636 | 0.81 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL17114637 | 0.81 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL17130390 | 0.81 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL19011828 | 0.81 | EPHX2 (0.83) | EPHX2EPHX1 | |
| SCHEMBL30954171 | 0.81 | EPHX2 (0.65) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129023-B1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020193448-A1 | MULTITARGET COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITAT DE BARCELONA (ES) | 2020-10-01 | — | — | WO | disclosed |
| US-10377744-B2 | Potent soluble epdxide hydrolase inhibitors | EICOSIS, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20170174665-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS, LLC | 2017-06-22 | — | — | US | disclosed |
| WO-2015148954-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS, LLC (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377744-B2 | Potent soluble epdxide hydrolase inhibitors | EPHX1, EPHX2, LTA4H | EPHX2 2/4885EPHX1 1/4885NPC1 2513/4885 |
| US-20170174665-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, LTA4H | EPHX2 2/4885EPHX1 1/4885NPC1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.